Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed
Mary Wu, Edward J Carr, Ruth Harvey, et al.
The Lancet (2022) Vol. 400, Iss. 10369, pp. 2193-2196
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
MacGregor Cox, Thomas P. Peacock, William T. Harvey, et al.
Nature Reviews Microbiology (2022) Vol. 21, Iss. 2, pp. 112-124
Open Access | Times Cited: 261
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
Delphine Planas, Timothée Bruel, Isabelle Staropoli, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 165
Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study
Lance Turtle, Mathew Thorpe, Thomas M Drake, et al.
PLoS Medicine (2023) Vol. 20, Iss. 1, pp. e1004086-e1004086
Open Access | Times Cited: 66
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
Andrew Evans, Cathy Qi, Jubril Omololu Adebayo, et al.
Journal of Infection (2023) Vol. 86, Iss. 4, pp. 352-360
Open Access | Times Cited: 43
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 100991-100991
Open Access | Times Cited: 32
Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 5, pp. 813-823
Open Access | Times Cited: 31
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
Dean Follmann, Meagan P. O’Brien, Jonathan Fintzi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
Delphine Planas, Timothée Bruel, Isabelle Staropoli, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 31
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform
Bang Zheng, John Tazare, Linda Nab, et al.
The Lancet Regional Health - Europe (2023) Vol. 34, pp. 100741-100741
Open Access | Times Cited: 16
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign
Marianne Shawe‐Taylor, David Greenwood, Agnieszka Hobbs, et al.
The Lancet (2024) Vol. 403, Iss. 10432, pp. 1133-1136
Open Access | Times Cited: 6
Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia
Eric Kalo, Ziad Basyouni, Gizelda Katz, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Open Access
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients
Timothée Bruel, Lou-Léna Vrignaud, Françoise Porrot, et al.
Med (2023) Vol. 4, Iss. 10, pp. 664-667
Open Access | Times Cited: 12
Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 4
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Francisco Javier Candel, Pablo Barreiro, Miguel Salavert, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1449-1449
Open Access | Times Cited: 11
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 9
A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance
Daniele Focosi
Viruses (2023) Vol. 15, Iss. 5, pp. 1048-1048
Open Access | Times Cited: 9
Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
Jorge Calderón‐Parra, Pablo Guisado‐Vasco, Rocío Montejano-Sánchez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 864-864
Open Access | Times Cited: 8
Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases
Bang Zheng, Jacqueline Campbell, Edward J Carr, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 11, pp. 2048-2058
Open Access | Times Cited: 8
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
(2024)
Open Access | Times Cited: 2
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 8
Open Access | Times Cited: 2
Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platform
John Tazare, Linda Nab, Bang Zheng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study
Andrew Evans, Cathy Qi, Lolu Adebayo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
Toby J L Humphrey, Davinder Dosanjh, Thomas F. Hiemstra, et al.
Trials (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top